US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas.
Back to Business
Business
October 7, 2026 at 4:20 AM
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
SCMP Business
Excerpt from SCMP Business.
